209 related articles for article (PubMed ID: 33947144)
1. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
[TBL] [Abstract][Full Text] [Related]
2. Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M; Lee C; Hong J; Kim J; Jeong JY; Park NJ; Kim JE; Park JY
Cancer Res Treat; 2023 Apr; 55(2):429-441. PubMed ID: 36470260
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
Froyen G; Geerdens E; Berden S; Cruys B; Maes B
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
[TBL] [Abstract][Full Text] [Related]
4. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.
Valentini V; Silvestri V; Bucalo A; Conti G; Karimi M; Di Francesco L; Pomati G; Mezi S; Cerbelli B; Pignataro MG; Nicolussi A; Coppa A; D'Amati G; Giannini G; Ottini L
Front Oncol; 2022; 12():1092201. PubMed ID: 36686738
[TBL] [Abstract][Full Text] [Related]
8. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
9. Key considerations for comprehensive validation of an RNA fusion NGS panel.
Barua S; Wang G; Mansukhani M; Hsiao S; Fernandes H
Pract Lab Med; 2020 Aug; 21():e00173. PubMed ID: 32613069
[TBL] [Abstract][Full Text] [Related]
10. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
11. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
[TBL] [Abstract][Full Text] [Related]
12. Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America.
Salvo M; González-Feliú E; Toro J; Gallegos I; Maureira I; Miranda-González N; Barajas O; Bustamante E; Ahumada M; Colombo A; Armisén R; Villamán C; Ibañez C; Bravo ML; Sanhueza V; Spencer ML; de Toro G; Morales E; Bizama C; García P; Carrasco AM; Gutiérrez L; Bermejo JL; Verdugo RA; Marcelain K
J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575676
[TBL] [Abstract][Full Text] [Related]
13. Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.
Pabla S; Andreas J; Lenzo FL; Burgher B; Hagen J; Giamo V; Nesline MK; Wang Y; Gardner M; Conroy JM; Papanicolau-Sengos A; Morrison C; Glenn ST
Oncotarget; 2019 Aug; 10(50):5181-5193. PubMed ID: 31497248
[TBL] [Abstract][Full Text] [Related]
14. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
15. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
16. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.
Eifert C; Pantazi A; Sun R; Xu J; Cingolani P; Heyer J; Russell M; Lvova M; Ring J; Tse JY; Lyle S; Protopopov A
Per Med; 2017 Jul; 14(4):309-325. PubMed ID: 28890729
[TBL] [Abstract][Full Text] [Related]
18. Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy.
Wang D; Ma K; Deng W; Li J; Xiang S; Zhang Y; Fu Y; Dai H; Huang B
Onco Targets Ther; 2021; 14():2423-2431. PubMed ID: 33854338
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R
PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149
[TBL] [Abstract][Full Text] [Related]
20. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
